EUVIMEDEUVIMED entdecken
Open Access

Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection

Skyler Rogers iD, Kelsey M Sumner, Yangyupei Yang iD, Emileigh Johnson, Ran Balicer, Alon Peretz, David Greenberg, Avital Hirsch iD, Mark A Katz, Florian Krammer iD, Arnold S Monto iD, Emily T Martin iD

The Journal of Infectious Diseases · 15.10.2026 · 234 (4) · 573-582

DOI: 10.1093/infdis/jiag351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 10.07.2026. Verfasst von Skyler Rogers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Neuraminidase, Antibodies, Viral, Influenza B virus, Influenza Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIH HHS, HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza vaccines are designed to induce hemagglutinin-inhibiting (HAI) antibodies rather than neuraminidase-inhibiting (NAI) antibodies; therefore, NAI antibodies’ protective effects need further investigation. Neuraminidase-inhibiting antibodies’ protective effects, independent of HAI antibodies, have been demonstrated for influenza A viruses, but not influenza B viruses (IBVs).

Methods

Employing H6NB reassortant virus targets, we evaluated NAI antibodies’ protective effects against IBV in sera from a prospective influenza vaccine effectiveness study among healthcare personnel (HCP) in Israel. Antibody titers against B/Brisbane/60/2008 and B/Phuket/3073/2013 were quantified by HAI and NAI assays. Matched NAI and HAI antibody titers from baseline and postvaccination sera were analyzed for the 2017–2018 influenza season.

Results

Laboratory-confirmed IBV infection was recorded in 64/262 HCP and influenza vaccination in 187/262 HCP. Vaccination did not consistently elicit rising NAI titers against vaccine strain B/Brisbane, with a geometric mean fold rise of 1.1 (95% CI: .9–1.3). However, comparing baseline NAI titers, geometric mean titer ratios were 1.50 (95% CI: 1.0–2.1) times higher against B/Brisbane and 2.5 (95% CI: 1.7–3.6) times higher against circulating B/Phuket in vaccinated versus unvaccinated HCP. Each 2-fold rise in NAI antibody titers reduced the hazard of symptomatic infection by 42% (95% CI: 36%–48%) against B/Phuket and 23% (95% CI: 13%–33%) against B/Brisbane, adjusting for HAI titers.

Conclusions

Neuraminidase-inhibiting antibodies were a strong correlate of protection against symptomatic IBV infection, with protective effects independent of those from HAI antibodies. These findings suggest that the use and standardization of neuraminidase content in influenza vaccines could provide broader protection against influenza.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuraminidaseAntibodies, ViralInfluenza B virusInfluenza VaccinesInfluenza, HumanViral ProteinsHumansProspective StudiesIsraelHemagglutination Inhibition TestsVaccine EfficacyFemale

Stichwörter der Autor:innen

antibodiescorrelates of protectionhealthcare personnelinfluenza Bneuraminidase

Substanzen

NeuraminidaseAntibodies, ViralInfluenza VaccinesViral ProteinsNA protein, influenza B virus

Autor:innen und Institutionen

  • Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA.
  • Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
  • School of Public Health, Faculty of Social Welfare and Health Studies, University of Haifa, Haifa, Israel.
  • Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel.
  • Saban Children's Hospital, Soroka University Medical Center, Be'er Sheva, Israel.

ORCID-Profile: Skyler Rogers, Yangyupei Yang, Avital Hirsch, Florian Krammer, Arnold S Monto, Emily T Martin

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • HHS
  • National Institutes of Health
  • Department of Health and Human Services

Zitieren

APA

Rogers, S., Sumner, K. M., Yang, Y., Johnson, E., Balicer, R., Peretz, A., Greenberg, D., Hirsch, A., Katz, M. A., Krammer, F., Monto, A. S., & Martin, E. T. (2026). Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection. The Journal of Infectious Diseases, 234(4), 573-582. https://doi.org/10.1093/infdis/jiag351

Vancouver

Rogers S, Sumner KM, Yang Y, Johnson E, Balicer R, Peretz A, et al. Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection. The Journal of Infectious Diseases. 2026;234(4):573-582. doi:10.1093/infdis/jiag351

BibTeX
@article{Rogers2026,
  author = {Rogers, Skyler and Sumner, Kelsey M and Yang, Yangyupei and Johnson, Emileigh and Balicer, Ran and Peretz, Alon and Greenberg, David and Hirsch, Avital and Katz, Mark A and Krammer, Florian and Monto, Arnold S and Martin, Emily T},
  title = {Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {234},
  number = {4},
  pages = {573--582},
  doi = {10.1093/infdis/jiag351}
}
Kostenlos starten →